Skip to main content
. Author manuscript; available in PMC: 2019 Nov 15.
Published in final edited form as: Cancer Res. 2019 Feb 17;79(10):2684–2696. doi: 10.1158/0008-5472.CAN-18-2864

Figure 5. MYC is amplified while NF-κB and IFN-γ signaling genes are deleted in the Low Immune Subgroup.

Figure 5

(A) Oncoprint figure for Low, Intermediate and High Immune group representing CNA of MYC, NF-κB and genes in the IFN-γ pathway with annotation of CTNNB1 expression and survival status. (B) Kaplan Meier plots for participants whose tumors showed MYC amplifications, NFKB1 deletions, and for a combination of MYC and NFKB1 CNAs in the whole dataset. Hazard ratios were calculated using the univariable Cox proportional hazard model.